



(51) International Patent Classification:

A61K 39/395 (2006.01) *C07K 14/735* (2006.01)
A61K 35/17 (2015.01) *C07K 16/28* (2006.01)
C07K 14/725 (2006.01) *C07K 16/30* (2006.01)
C07K 14/705 (2006.01) *A61K 39/00* (2006.01)

(21) International Application Number:

PCT/EP2018/057566

(22) International Filing Date:

26 March 2018 (26.03.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

17163090.8 27 March 2017 (27.03.2017) EP

(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).

(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Overlook at Great Notch, 150 Clove Road,

8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).


(72) Inventors: **STUBENRAUCH, Kay-Gunnar**; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). **MOESSNER, Ekkehard**; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). **KLEIN, Christian**; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). **DAROWSKI, Diana**; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH).

(74) Agent: **BRODBECK, Michel**; Grenzacherstrasse 124, 4070 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: IMPROVED ANTIGEN BINDING RECEPTORS


Figure 1A



scFv Format

ATM = anchoring transmembrane domain
 CSD = co-stimulatory signaling domain
 SSD = stimulatory signaling domain

Figure 1B



Fab Format

(57) Abstract: The present disclosure generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely the application deals with an engineered Fc receptor consisting of a CD3 intracellular domain coupled to CD28 internal and transmembrane domains. The extracellular part preferably consists of an anti Pro329Gly antibody variable domain. Uses in cancer therapy and diagnosis

[Continued on next page]

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to the identity of the inventor (Rule 4.17(i))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*